Characterizing clearance of helper adenovirus by a clinical rAAV1 manufacturing process

Biologicals. 2008 Jan;36(1):7-18. doi: 10.1016/j.biologicals.2007.04.001. Epub 2007 Jul 19.


Recombinant adeno-associated viral vectors (rAAV) are being developed as gene therapy delivery vehicles and as genetic vaccines, and some of the most scaleable manufacturing methods for rAAV use live adenovirus to induce production. One aspect of establishing safety of rAAV products is therefore demonstrating adequate and reliable clearance of this helper virus by the vector purification process. The ICH Q5A regulatory guidance on viral safety provides recommendations for process design and characterization of viral clearance for recombinant proteins, and these principles were adapted to a rAAV serotype 1 purification process for clinical vectors. Specific objectives were to achieve overall adenovirus clearance factors significantly greater than input levels by using orthogonal separation and inactivation methods, and to segregate adenovirus from downstream operations by positioning a robust clearance step early in the process. Analytical tools for process development and characterization addressed problematic in-process samples, and a viral clearance validation study was performed using adenovirus and two non-specific model viruses. Overall clearance factors determined were >23 LRV for adenovirus, 11 LRV for BVDV, and >23 LRV for AMuLV.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / isolation & purification*
  • Adenoviridae / physiology
  • Capsid Proteins / genetics
  • Capsid Proteins / isolation & purification
  • Capsid Proteins / metabolism
  • Cell Line
  • Dependovirus / genetics
  • Dependovirus / isolation & purification*
  • Dependovirus / physiology*
  • Genetic Vectors / biosynthesis*
  • Genetic Vectors / genetics
  • Helper Viruses / isolation & purification*
  • Helper Viruses / physiology
  • Hot Temperature
  • Humans
  • Virus Inactivation


  • Capsid Proteins